Remove

U.S. Patient and Trademask Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number		10567762	
Filing Date		2005-06-09	
First Named Inventor TAKA		SHI KENMOKU ET AL.	
Art Unit		1711	
Examiner Name G. M		SH	
Attorney Docket Number		03500 103897	

					0.5.1	AIENIS		Helliove			
Examiner Cite Initial* No Patent Number Kind Code1		Issue E	Date	Name of Patentee or Applicant of cited Document		Releva		Lines where ges or Relev			
	1	4265247	A	1981-05	i-05	Lenz et al.					
	2	6645743	B1	2003-11	i-11	.Honma et al.					
	3	6521429	B2	2003-02	-18	Honma et al.					
If you wish	h to a	dd additional U.S. Pater	nt citatio	n inform	ation pl	ease click the	Add button.		Add		
			U.S.P	ATENT	APPLIC	CATION PUB	LICATIONS		Remove		
Examiner Initial*	Cite No	Cite Publication Number Kind Publication Name of		Name of Pate of cited Docu	entee or Applicant ment	Releva		Lines where ges or Relev			
	1	20070073006	A1	2007-03	1-29	Kenmoku et al	L				
If you wis	h to a	dd additional U.S. Publi	shed Ap	plication	citation	n information p	please click the Ad	d button	Add		
				FOREIG	SN PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴	Gind Publication Date Name of Patenter Applicant of cited Document		e or	where Rel	or Relevant	Ts
	1	2005/121204	wo		A2	2005-12-22	CANON KK				

U.S. PATENTS

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10567762
Filing Date		2005-06-09
First Named Inventor TAKA		SHI KENMOKU ET AL.
Art Unit		1711
Examiner Name	G. ME	SH
Attomory Docket Number		03500 103907

	2	59-190945	JÞ.	A	1984-10-29	JAPAN SYNTHETIC RUBBER CO. LTD.		
	3	2-3415	JP	A	1990-01-09	NIPPON SHOJI KK		
	4	2005/121208	wo	A1	2005-12-22	CANON KK		
	5	2005/121205	wo	A2	2005-12-22	CANON KK		
If you wis	h to a	dd additional Foreign P	atent Document	citation	information pl	ease click the Add buttor		
			NON-PATER	NT LITE	RATURE DO	CUMENTS	Remove	
Examiner Initials*	Examiner Cite Include name of the author (in CAPITAL LETTERS), ittle of the article (when appropriate), ittle of the item (look, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.							
Militael Trollatia et al., "Hydrophilic Aliphatic Polyesters: Design, Synthesis, and Ring-Opening Polymertzation of Functional Cyclic Esters," 33 Macromot. 4619-27 (2000).								
	S. Ponsart et al., "A Novel Route to Poly(s-caprolactone)-Based Copolymers via Anionic Derivatization," 1 Biomolecules 275-81 (2000).							
	Benjamin Studner et al., "Lactic Acid-Based Functionalized Polymers via Copolymerzation and Chemical Modification," 4 Macromot. Biosci. 232-37 (2004).							
	Bryan Parrish et al., "Functional Polyesters by Ring-Opening Polymerization of crally(6-valerolactone)," 87 Polymer. Mater: So. & Eng. 254-55 (2002).							
	5 C.P. Radano et al., "Synthesis of Novel Biodegradable Copolyesters Using Olefin Metathesis," 43(2) Polymer Reprints 727-28 (2002).							

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10567762	
Filing Date		2005-06-09	
First Named Inventor TAKA		ISHI KENMOKU ET AL.	
Art Unit		1711	
Examiner Name G. Mi		ESH	
Attorney Docket Number		03500 103897	

6	Tetsuji Yamaoka et at., "Synthesis and Properties of Malic Acid Contaming Functional Polymers," 25 Intl. J. Biol Micromot. 265-71 (1999).	
7	Lindsay H. Briggs et al., "Degradation of the Lancelerol Side-Chain," J.C.S. Perkin I, 806-09 (1973).	
8	Organic Synthesis, vol. 4, pp. 698-99 (1963).	
9	Harry R. Allocok et al., "Reactions of Steroid Salts with Hexachiorocyclotriphosphazane," 46 J. Org. Chem. 13-22 (1991).	
10	J.K. Stille et al., "Tetracyclic Dienes. I. The Diels-Alder Adduct of Norbornsdiene and Cyclopentadiene," 81 J. Am. Chem. Soc. 4273-75 (August 1959).	
11	Marie-Maud Bear et al., "Preparation of a Bacterial Polyester with Carboxy Groups in Side Chans," 4 Chemistry 289-43 (2001).	
12	Dirk Brohm et al., "Solid-Phase Synthesis of Dysdiolode-Derived Protein Phosphatase Inhibitors," 124 J. Am. Chem. Soc. 13171-78 (2002).	
13	Jon D. Stewarf et al., "Recombinant Baker's Yeast as a Whole-Cell Catalyst for Asymmetric Baeyer-Villiger Oxidations," 120(15) J. Am. Chem. Soc. 3541-48 (April 1998).	

If you wish to add additional non-patent literature document citation information please click the Add button Add

Examiner Signature Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

150e Knic Ooke of USPTO Detern Decuments at year, USPTO DOLY or MEDF 98154. * Enter of this that issued the document, by the baseleter ock (MPDC Standard ST.3). **Straphenes plant of courseth, the endeated on the year of the register term process the self-ant-invitor of the plant document. **Invitor of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. **Applicant is to place a check mark here if English targingues the resistance is attached.**

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10567762	
Filing Date		2005-06-09	
First Named Inventor	TAKA	SHI KENMOKU ET AL.	
Art Unit		1711	
Examiner Name	G. ME	SH	
Attorney Docket Number		03500.103897	

CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.98 to make	the appropriate selection(s):
---------------	----------	------------------	-------------------------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(eV1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any involved designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Jason M. Okun/	Date (YYYY-MM-DD)	2007-05-15
Name/Print	Jason M. Okun	Registration Number	48512

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to life (and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 122 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Department of Commence, P. 0 Box 1449, Alexandri, V.S. 2211-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1459, Alexandria, V.S. 22131-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.